Medicure (MCUJF) Stock News

Medicure (OTC:MCUJF) reported Q1 2026 net revenue of $7.9 million, up from $5.4 million in Q1 2025, driven by ZYPITAMAG and the Pharmacy Business Segment. Adjusted EBITDA was $280,000, with a net loss of $406,000 ($0.04/share) and R&D spending of $855,000.

AGGRASTAT revenue declined to $979,000, while unrestricted cash fell to $1.5 million at March 31, 2026. A conference call is scheduled for May 25, 2026.

Medicure (OTC:MCUJF) reported 2025 results and scheduled a conference call for April 27, 2026 at 8:30 AM ET.

Key metrics: total net revenue $28.9M (2025) vs $21.9M (2024); AGGRASTAT sales $5.7M; Pharmacy revenue $20.3M; ZYPITAMAG sales $6.5M; R&D $3.2M; Adjusted EBITDA -$1.5M; Net loss $7.1M ($0.68/share); cash $3.8M.

Medicure (OTC:MCUJF) announced that Dr. Neil Owens has resigned as President and Chief Operating Officer, effective on or before May 31, 2026.

Dr. Albert D. Friesen, CEO and chair, will assume the responsibilities of President to maintain continuity while the company continues executing its strategic priorities.

Medicure (OTC:MCUJF) reported Q3 2025 results for the quarter ended September 30, 2025. Total net revenue was $8.2M vs $5.2M a year earlier, driven by pharmacy acquisitions and increased ZYPITAMAG® sales. AGGRASTAT® revenue fell to $1.0M from $1.9M amid generic pricing pressure. Adjusted EBITDA was negative $597k and net loss was $1.4M (‑$0.13/share) versus net income $680k (0.07/share) in Q3 2024. Unrestricted cash was $4.1M at Sept 30, 2025, down from $7.2M at Dec 31, 2024. R&D investment was $717k, supporting a Phase 3 trial for MC-1 for PNPO deficiency.

Medicure (OTC PINK: MCUJF; TSXV: MPH) will present its Q3 2025 financial results via conference call on Thursday, November 20, 2025 at 8:30 AM ET. The company said the financial statements for the quarter ended September 30, 2025 will be filed after market close on November 19, 2025. Management will review results and take questions during the call.

Call details: 7:30 AM CT / 8:30 AM ET; Toll free 1 (888) 506-0062; International 1 (973) 528-0011; Participant code 514899. A live webcast will be available at the provided link and a recording will be posted on the company website.

Medicure (OTC:MCUJF) reported its Q2 2025 financial results, showing improved performance with total net revenue of $6.7 million, up from $5.2 million in Q2 2024. The company's net loss narrowed to $786,000 ($0.08 per share) from $1.2 million ($0.12 per share) year-over-year.

Key revenue contributors included Marley Drug business ($3.1 million), AGGRASTAT® ($1.7 million), ZYPITAMAG® ($1.7 million), Gateway Pharmacy ($764,000), and West Olympia Pharmacy ($328,000). The company invested $741,000 in R&D, focusing on a Phase 3 trial of MC-1 for PNPO deficiency. Cash position stood at $4.7 million as of June 30, 2025, down from $7.2 million at year-end 2024.

Medicure (OTC:MCUJF), a pharmaceutical company focused on the US healthcare market, has scheduled its Q2 2025 financial results conference call for August 21, 2025, at 8:30 AM ET. The company will file its Q2 2025 financial statements after market close on August 20, 2025.

The conference call will be accessible via toll-free and international dial-in numbers, with a participant access code of 850331. A live webcast will be available, and management will conduct a Q&A session following the presentation. A recording will be made available on the company's website after the event.

Medicure Inc. (MCUJF) has successfully closed the acquisition of West Olympia Pharmacy Inc. through its U.S. subsidiary Medicure Pharma Inc. This strategic acquisition, along with Gateway Medical Pharmacy, is projected to generate approximately $10 million in additional annual net revenue and contribute to overall net income. The deal strengthens Medicure's direct-to-consumer pharmacy business and supports growth of its key products ZYPITAMAG and BRENZAVVY. Notably, the transaction was completed without requiring financing or acquiring debt, and no finder fees were involved. This acquisition represents a significant step in Medicure's strategic expansion plan in the U.S. healthcare market.

Medicure (MCUJF) reported its Q1 2025 financial results, showing mixed performance across its pharmaceutical portfolio. Total net revenue reached $5.5 million, down from $5.7 million in Q1 2024. The company's Marley Drug business showed growth with revenue of $3.1 million (up from $2.7 million), while AGGRASTAT sales declined to $1.7 million (from $2.3 million). ZYPITAMAG insured sales decreased to $519,000 (from $777,000). The newly acquired Gateway Pharmacy contributed $175,000 in revenue. The company reported a net loss of $694,000 ($0.07 per share) compared to net income of $51,000 in Q1 2024. Adjusted EBITDA decreased to $28,000 from $359,000. Cash position improved to $7.2 million from $6.1 million year-over-year, with positive operating cash flow of $656,000.